Literature DB >> 17939311

Diabetic foot osteomyelitis: usefulness of erythrocyte sedimentation rate in its diagnosis.

U H Malabu1, K A Al-Rubeaan, M Al-Derewish.   

Abstract

BACKGROUND: Recently, ESR was reported to have a useful diagnostic value in detecting diabetic osteomyelitis. The test has been performed in a limited number of patients. This laboratory parameter is simple and could be routinely performed in developing countries where diabetes and its complication are increasingly being encountered.
OBJECTIVE: To evaluate the reliability of erythrocyte sedimentation rate (ESR) in differentiating diabetic osteomyelitis from cellulitis, and to compare its diagnostic value with other hematological indices.
METHODS: In a one-year prospective study, forty -three adult diabetic patients with foot ulcers were assessed at King Abdulaziz University Hospital Diabetes Center Riyadh from 1st January to 31st December 2005. ESR was compared with other hematological profiles in differentiating osteomyelitis from cellulitis.
RESULTS: ESR, white blood cell count (WBC), platelet count, and red cell distribution width (RDW) were higher in patients with osteomyelitis than in patients with cellulitis (p<0.0001 for ESR; others p<0.05). In contrast, haematocrit and haemoglobin levels were lower in patients with osteomyelitis than in patients with cellulitis (p<0.0001). Overall, the efficiency of the haematological parameters in correctly diagnosing diabetic osteomyelitis from cellulitis was highest for ESR > 70 mm/hr (92%), followed by haematocrit < 36% (89%), haemoglobin < 12 g/dl (85%), platelet count > 400x10(9) (69%), RDW > 14.5 (65%), and WBC >11x10(9) (63%).
CONCLUSION: It is concluded that of the haematological parameters, ESR has the best diagnostic discrimination between diabetic foot osteomyelitis from cellulitis. Further studies on larger population in this environment are however indicated.

Entities:  

Mesh:

Year:  2007        PMID: 17939311

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  7 in total

1.  Factors associated with lower-extremity amputation in patients with diabetic foot ulcers in a Chinese tertiary care hospital.

Authors:  Zi Guo; Chun Yue; Qiang Qian; Honghui He; Zhaohui Mo
Journal:  Int Wound J       Date:  2019-08-25       Impact factor: 3.315

2.  What are the Optimal Cutoff Values for ESR and CRP to Diagnose Osteomyelitis in Patients with Diabetes-related Foot Infections?

Authors:  Lawrence A Lavery; Junho Ahn; Easton C Ryan; Kavita Bhavan; Orhan K Oz; Javier La Fontaine; Dane K Wukich
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

Review 3.  Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem.

Authors:  Bulent M Ertugrul; Benjamin A Lipsky; Oner Savk
Journal:  Diabet Foot Ankle       Date:  2013-11-05

Review 4.  Optimal management of diabetic foot osteomyelitis: challenges and solutions.

Authors:  José Luis Lázaro Martínez; Yolanda García Álvarez; Aroa Tardáguila-García; Esther García Morales
Journal:  Diabetes Metab Syndr Obes       Date:  2019-06-21       Impact factor: 3.168

Review 5.  A systematic review showing the lack of diagnostic criteria and tools developed for lower-limb cellulitis.

Authors:  M Patel; S I Lee; R K Akyea; D Grindlay; N Francis; N J Levell; P Smart; J Kai; K S Thomas
Journal:  Br J Dermatol       Date:  2019-06-28       Impact factor: 9.302

6.  Utility of Blood Parameters to Detect Complications during Long-Term Follow-Up in Patients with Diabetic Foot Osteomyelitis.

Authors:  Aroa Tardáguila-García; Yolanda García Álvarez; Esther García-Morales; Francisco Javier Álvaro-Afonso; Irene Sanz-Corbalán; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

7.  Serum procollagen type 1 N propeptide: A novel diagnostic test for diabetic foot osteomyelitis - A case-control study.

Authors:  Oliver G Hayes; Venkat N Vangaveti; Usman H Malabu
Journal:  J Res Med Sci       Date:  2018-05-30       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.